<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95840">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995656</url>
  </required_header>
  <id_info>
    <org_study_id>15197</org_study_id>
    <secondary_id>I7D-FW-SGAA</secondary_id>
    <nct_id>NCT01995656</nct_id>
  </id_info>
  <brief_title>A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY3108743 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Singapore: Health Sciences Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of the study drug
      known as LY3108743 in healthy participants and in participants with type 2 diabetes.

      The study will also investigate how LY3108743 affects the levels of blood sugar and other
      naturally occurring substances (e.g. hormones that control the way sugar is used) in the
      body, how much of the study drug gets into the blood stream, and how long it takes the body
      to get rid of it.

      Information about any side effects that may occur will be collected. The study is expected
      to last approximately 7 to 8 weeks for each participant.

      The study will have up to 3 parts. Participants may enroll in only one part.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Pre-dose up to Day 6 (5 days post-dose)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Change from Baseline up to 24 Hours in Level of Blood Glucose Before and After a Standard Meal</measure>
    <time_frame>Baseline up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY3108743</measure>
    <time_frame>Baseline up to 48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve (AUC) of LY3108743</measure>
    <time_frame>Baseline up to 48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo - Healthy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3108743 - Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Diabetes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3108743 - Diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3108743 - Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Capsule</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo - Healthy</arm_group_label>
    <arm_group_label>Placebo - Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3108743 - Capsule</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3108743 - Healthy</arm_group_label>
    <arm_group_label>LY3108743 - Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Solution</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo - Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3108743 - Solution</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3108743 - Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a male, or a female who cannot become pregnant, and who is either a healthy
             participant, or who has type 2 diabetes

          -  Have a body mass index (BMI) of 18.5 to 40.0 kilogram per square meter (kg/m^2),
             inclusive, at screening

          -  Have normal blood pressure

          -  Participants with diabetes must not be taking any anti-hyperglycemic medications with
             the exception of metformin. If on metformin, participants must be on a stable
             treatment regimen for at least for 4 weeks prior to screening

          -  Participants with diabetes must have a hemoglobin A1c (HbA1c) level between 6 to 11%,
             inclusive, at screening

        Exclusion Criteria:

          -  Have previously completed or withdrawn from this study

          -  Have or used to have health problems or laboratory test results or electrocardiogram
             (ECG) readings that, in the opinion of the doctor, could make it unsafe to
             participate or could interfere with understanding the results of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>November 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
